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ABSTRACT
FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, 
with a therapeutic peptide based on this protein, ALM201, shortly entering phase  
I/II clinical trials. Here, we evaluated FKBPL’s prognostic ability in primary breast 
cancer tissue, represented on tissue microarrays (TMA) from 3277 women recruited 
into five independent retrospective studies, using immunohistochemistry (IHC). In 
a meta-analysis, FKBPL levels were a significant predictor of BCSS; low FKBPL levels 
indicated poorer breast cancer specific survival (BCSS) (hazard ratio (HR) = 1.30, 
95% confidence interval (CI) 1.14–1.49, p < 0.001). The prognostic impact of FKBPL 
remained significant after adjusting for other known prognostic factors (HR = 1.25, 95% 
CI 1.07–1.45, p = 0.004). For the sub-groups of 2365 estrogen receptor (ER) positive 
patients and 1649 tamoxifen treated patients, FKBPL was significantly associated with 
BCSS (HR = 1.34, 95% CI 1.13–1.58, p < 0.001, and HR = 1.25, 95% CI 1.04–1.49,  
p = 0.02, respectively). A univariate analysis revealed that FKBPL was also a significant 
predictor of relapse free interval (RFI) within the ER positive patient group, but it 
was only borderline significant within the smaller tamoxifen treated patient group 
(HR = 1.32 95% CI 1.05–1.65, p = 0.02 and HR = 1.23 95% CI 0.99–1.54, p = 0.06, 
respectively). The data suggests a role for FKBPL as a prognostic factor for BCSS, 
with the potential to be routinely evaluated within the clinic.
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INTRODUCTION
Considerable research has been dedicated to 
identifying novel prognostic markers for breast cancer; 
however, the current panel of biomarkers available is 
still limited. Prognostic markers are routinely considered 
during disease management, with patients placed into risk 
groups depending upon; tumour size, grade and stage, as 
well as lymph-node and hormone-receptor status (reviewed 
in [1]). However, the ability of these markers to predict 
disease progression and tumor recurrence is often limited. 
Following the discovery of the role of estrogen in driving 
breast cancer development, drugs targeting estrogen 
receptor (ER) signalling [2, 3], i.e. endocrine therapies, 
have improved the survival of women with estrogen-driven 
breast cancer [4, 5]. Identifying patients who could benefit 
from endocrine therapy has become increasingly important, 
considering that very few women with ER-positive, node-
negative tumors derive a long term benefit from endocrine 
therapy. The 2011 overview from the Early Breast Cancer 
Trialists Collaborative Group (EBCTCG) reported that with 
a median follow-up of 13 years [6], 5 years of tamoxifen 
compared to no endocrine therapy resulted in only a 9% 
absolute reduction in breast cancer-related death at 15 years 
(24% versus 33%), and the risk of breast cancer mortality 
was reduced by 30% (relative risk (RR) for death 0.70, 
95% CI, 0.64–0.75). Some women clearly present with 
de novo resistance to tamoxifen treatment, whilst others 
acquire resistance [7]. Furthermore, 20–25% of patients 
receiving endocrine therapy discontinue treatment because 
of the side effects. Strategies to predict whether early stage 
breast cancer patients are likely to benefit from the addition 
of more appropriate targeted therapies or chemotherapy 
earlier, are needed in order to prevent further development 
of disease and to increase the survival rates; which patients 
absolutely require chemotherapy is therefore a major 
clinical question. The identification of additional prognostic 
markers could also help to identify patients who are unlikely 
to experience tumor recurrence and would therefore 
yield no therapeutic benefit from highly toxic systemic 
chemotherapies. Therefore, there is a need for additional 
prognostic markers to be developed in order to identify 
those patients who are likely to progress or relapse [8].
Since the mid-1970s, pathological analysis of 
breast tumours, usually via IHC staining, has been used 
to determine the ER and progesterone receptor (PR) 
status of the tumor, with both markers having the ability 
to indicate the likelihood of recurrence and response 
to endocrine therapies [9]. More recently, molecular 
assays such as Oncotype Dx (measuring 21 genes) and 
MammaPrint (measuring 70 genes) [10, 11], which assess 
risk of distant recurrence, are showing promise; however, 
the principle disadvantage of Oncotype DX® is the 
existence of a large “intermediate” group of patients for 
whom the correct treatment choice remains unclear. This 
further demonstrates the need for additional biomarkers, 
in order to distinguish these patients. The cheaper 5 
marker IHC-based test, MammoStrat, which calculates 
a risk index score [12] is also showing promise, but the 
addition of single IHC biomarkers to standard ER/PR/
Her2/Ki67 evaluation to improve sensitivity would still be 
advantageous, especially in terms of identifying patients 
who are at risk of relapse or disease progression. Recently, 
the PAM50 gene signature added significant prognostic 
information beyond the Oncotype DX® Recurrence 
Score® in estimating the likelihood of distant recurrence in 
hormone receptor positive, post-menopausal breast cancer 
patients and may help to identify women who are at high 
risk of late recurrence and who may benefit from either 
more intensive treatment (i.e. chemotherapy) or extended 
endocrine treatment [13–15].
FK506 binding protein like - FKBPL, is a 
divergent member of the immunophilin protein family. 
This family of proteins have wide-ranging intra- and 
extra- cellular roles in a host of diseases through their 
chaperoning function and peptidylprolyl isomerase 
(PPIase) activity [16]. FKBPL is clearly divergent, with 
no PPIase activity, whilst retaining its tetratricopeptide 
repeat (TPR) domain, important for the interaction with 
the molecular chaperone Hsp90 [17], and is emerging as 
a key negative regulator of tumor growth, angiogenesis 
and metastasis [18, 19]. We have shown previously that 
FKBPL is a naturally secreted anti-angiogenic protein that 
inhibits blood vessel development by targeting the cell 
surface receptor, CD44, on actively migrating endothelial 
cells, thereby inhibiting migration and vessel formation 
[19]. A ‘first-in-class’ FKBPL-based anti-angiogenic 
therapeutic peptide, ALM201, will shortly enter a multi-
centre cancer clinical trial (EudraCT 2014–001175-31) 
[20]. Furthermore, we have demonstrated that the ability 
of FKBPL to bind CD44 makes it useful for targeting 
cancer stem cells (CSCs), which express high levels of 
CD44 [21]. FKBPL has also been implicated in steroid 
hormone receptor signalling due to its intracellular role 
in association with the molecular chaperone Hsp90 [22, 
23]. We have also demonstrated the ability of RBCK1 to 
regulate intracellular FKBPL levels, through interaction 
with Hsp90 [24]. In breast cancer cells, over-expression 
of FKBPL resulted in reduced cell proliferation, due to 
stabilization of newly synthesised cyclin-dependent kinase 
inhibitor, p21 [25]. FKBPL levels have also been shown 
to correlate with sensitivity or resistance to tamoxifen 
therapy in vitro; with cells over-expressing FKBPL being 
more sensitive to treatment, compared with the resistance 
shown when FKBPL levels were reduced with FKBPL-
targeted siRNA [23]. This resistance is thought to be the 
result of reduced p21 stabilization, which in turn leads to 
hyperphosphorylation of ERα at the Ser118 residue, altering 
the conformation of ERα so that tamoxifen can no longer 
bind [26]. Furthermore, in three of five publically available 
microarray datasets totalling 484 patients, high FKBPL 
mRNA levels were shown to correlate with improved 
overall survival and increased distant metastasis-free 
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survival [23]. In addition, patients treated with tamoxifen 
also show a trend towards significance between high 
FKBPL levels and improved survival [23]. Therefore, 
since FKBPL demonstrates clear inhibitory roles in tumor 
growth and progression through a variety of independent 
mechanisms, its potential as a prognostic biomarker was 
further explored here in 5 independent TMA cohorts using 
IHC. An individual patient data meta-analysis was then 
undertaken to determine whether FKBPL could be used 
prognostically or had value in identifying patients most 
likely to benefit from tamoxifen therapy or who would be 
likely to benefit from adjuvant chemotherapy, particularly 
patients with early stage, ER+, LN-, Her2- breast cancer.
RESULTS
Validation to demonstrate IHC assay 
reproducibility, portability and  
application to TMAs
The anti-FKBPL polyclonal antibody (Proteintech, 
UK) was verified for specificity via Western blotting, and 
optimized for IHC using cell pellet arrays of parental (MCF-
7 and MDA-MB-231) and FKBPL overexpressing (3.1D2, 
3.1D9; derived from MCF-7 and A3; derived from MDA-
MB-231 [23]) cell lines or in MCF-7 cells where FKBPL was 
knocked down using an FKBPL-targeted siRNA [21] (Figure 
1A). FKBPL staining intensity was clearly stronger in 3.1D2 
and A3 compared to parental MCF-7 and MDA-MB-231 
cells, respectively; mirroring western blot analysis. Likewise 
staining intensity was reduced following FKBPL-mediated 
siRNA knockdown compared to MCF-7 parent cells.
Full-face breast cancer (n = 140) and representative 
TMA sections obtained from Nottingham were stained 
and scored to ensure that TMAs were fit for purpose. For 
scoring FKBPL, sections/cores were assigned overall 
FKBPL staining intensity scores; 0, 1+, 2+ or 3+ providing 
over 20% of the core consisted of tumor tissue (Figure 1B). 
An intraclass correlation coefficient (ICCC) of 0.61 (95% 
confidence interval (CI) 0.49–0.70) between the full face 
sections and matched TMA sections for Run 1 was obtained 
and 0.65 (95% CI 0.55–0.74) for Run 2 (Supplementary 
Figure 1). These ICCCs demonstrate an acceptable measure 
of agreement between full face sections and the matched 
cores, confirming that FKBPL staining in TMA cores is 
representative of staining in full-face tissue sections and, 
therefore, that TMAs are suitable for use in the analysis of 
FKBPL across breast cancer TMAs [21–23].
To assess inter-lab variability, IHC staining of TMAs 
(n = 200) was carried out at three different locations, 
Belfast, Dublin and Toronto on three independent platforms, 
on consecutively cut sections and scored blindly by four 
independent scorers. Two staining runs were performed 
and independently scored by 4 individuals. The ICCC 
agreement between individual scorers for each staining 
run was 0.57 (95% CI 0.50–0.64) for run 1 and 0.62 (95% 
CI 0.52–0.67) for run 2, demonstrating an acceptable level 
of agreement between sites. The ICCC for 4 individual 
scorers across the two staining runs ranged from 0.61 
(95% CI 0.42–0.73) to 0.90 (0.86–0.92), displaying 
good reproducibility. The data demonstrates reasonable 
assay portability as the analyses were carried out on 
consecutively cut sections and stained on three independent 
platforms. After the third and final training session for the 
staining and scoring methodology for FKBPL analysis, the 
ICCC between scorers reached 0.8 (95% CI 0.77–0.82), 
suggesting good correlation between scorers [36].
The reliability of manual IHC evaluation of FKBPL 
staining with image analysis software to quantitatively 
score FKBPL cytoplasmic staining was assessed within 263 
tumour cores from cohort I. The median automated scores 
tended to increase as the manual scoring groups increased, 
although there appeared to be considerable overlap between 
the automated and manual scores with reasonable ICCCs for 
both scorers (Supplementary Figure 2), suggesting reasonable 
agreement between automated and manual scoring.
Evaluation of FKBPL expression and breast 
cancer specific survival
An individual patient data meta-analysis was carried 
out using five TMA cohorts in order to fully determine 
the ability of FKBPL to predict outcome across the whole 
patient cohort (n = 3277). The patient clinico-pathological 
variables are shown for all five cohorts (Table 1), with the 
distribution of variables remaining similar throughout. The 
median FKBPL histoscore value over the whole 5 cohorts 
was 190 (interquartile range 150–200). The median 
FKBPL value for cohort IV of 156 was far lower than that 
of the other cohorts; with two thirds of patients with low 
FKBPL levels in cohort IV (Table 1).
With a median follow-up of 12 years (interquartile 
range 10–15 years), there were a total of 913 (28%) breast 
cancer deaths and 1295 (40%) recurrences within the 
combined cohort of 3277 patients. Within the individual 
cohorts, breast cancer specific survival (BCSS; Figure 2) 
was significantly different across FKBPL expression 
groups within cohorts I (p = 0.004, Figure 2A), II (p = 
0.04, Figure 2B) and III (p = 0.001, Figure 2C), but not 
within cohorts IV (p = 0.93, Figure 2D) and V (p = 0.36, 
Figure 2E) with lower FKBPL levels associated with poor 
BCSS (e.g. within cohort I: Hazard ratio (HR) = 1.71 (95% 
Confidence Interval (CI) 1.19–2.47, Figure 3). The meta-
analysis of these five cohorts (n = 3277) was performed 
using a one stage random effects model, as there appeared 
to be some heterogeneity between the cohorts (χ2 = 8.8, 
p = 0.07, Figure 3). Patients with lower FKBPL levels had 
significantly shorter BCSS than those with higher FKBPL 
levels (HR = 1.31, 95% CI 1.15–1.50, p < 0.001, Figure 3). In 
a multivariate random effects analysis, the effect of FKBPL 
on BCSS remained significant after adjusting for other 
known prognostic factors, including; tumor size, grade, nodal 
status, ER and PR status with time dependent covariates 
Oncotarget12212www.impactjournals.com/oncotarget
(HR = 1.25, 95% CI 1.07–1.45, p = 0.004), and after the 
addition of Her2 status as a time dependent covariate 
(HR = 1.21, 95% CI 1.06–1.42, p = 0.02). FKBPL was also 
significant after adjusting for the Nottingham Prognostic 
Index (NPI) (HR = 1.31, 95% CI 1.14–1.50, p = 0.0002); 
which was available in cohorts I, II, III, V (>3000 patients).
Evaluation of FKBPL expression and BCSS in 
endocrine therapy treated patients
There was some heterogeneity between cohorts 
when considering the effect of FKBPL expression on 
BCSS within the subgroup of 1649 tamoxifen treated 
Figure 1: Optimisation of FKBPL antibody for IHC. (A) Optimisation of the FKBPL anti-body for IHC staining. Specificity 
was verified via Western blotting, and optimized for IHC using cell pellet arrays of parental (MCF-7 and MDA-B-231) and FKBPL 
overexpressing (3.1D2, 3.1D9; derived from MCF-7 and A3; derived from MDA-231) cell lines or following siRNA-mediated knockdown 
of FKBPL in MCF-7 cells. (B) Various expression levels of FKBPL protein in invasive breast carcinoma. Images (x10) represent tumour 
sections with absent (0), low (1+), moderate (2+) and high (3+) immunohistochemical staining intensity for FKBPL.
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Table 1: Associations between clinico-pathological criteria in breast cancer samples across the five 
cohorts included in the meta-analysis
Cohort I Cohort II Cohort III Cohort IV Cohort V
N 290 1214 492 112 1169
Characteristics
Treated with 
tamoxifen 140 (48%) 445 (37%) 157 (32%) 67 (60%) 840 (72%)
FKBPL histoscore
Median (IQR) 187 (122–200) 180 (165–200) 200 (150–200) 156 (117–200) 200 (150–200)
Low 146 (50%) 728 (60%) 216 (44%) 76 (68%) 400 (34%)
High 144 (50%) 486 (40%) 276 (56%) 36 (32%) 769 (66%)
Tumor size
< 20 mm 100 (34%) 592 (49%) 306 (62%) 30 (27%) 417 (36%)
>= 20 mm 189 (65%) 615 (50%) 186 (38%) 60 (53%) 712 (61%)
Unknown 1 (1%) 7 (1%) 0 22 (20%) 40 (3%)
Tumor grade
1 34 (12%) 211 (17%) 123 (25%) 6 (6%) 253 (22%)
2 112 (39%) 412 (34%) 203 (41%) 38 (34%) 494 (42%)
3 140 (48%) 584 (48%) 165 (33%) 51 (46%) 414 (35%)
Unknown 4 (1%) 7 (1%) 1 (1%) 17 (15%) 8 (1%)
Nodal status
Negative 81 (28%) 639 (53%) 279 (57%) 44 (39%) 801 (68.5%)
Positive 207 (71%) 442 (36%) 161 (33%) 41 (37%) 367 (31.4%)
Unknown 2 (1%) 133 (11%) 52 (10%) 27 (24%) 1 (0.1%)
ER status
Negative 99 (34%) 287 (24%) 73 (15%) 28 (25%) 294 (25%)
Positive 141 (49%) 891 (73%) 419 (85%) 69 (62%) 845 (72%)
Unknown 50 (17%) 36 (3%) 0 15 (13%) 30 (3%)
PR status
Negative 88 (30%) 458 (38%) 157 (32%) 39 (35%) 245 (21%)
Positive 150 (52%) 687 (56%) 335 (68%) 53 (47%) 898 (77%)
Unknown 52 (18%) 69 (6%) 0 20 (18%) 26 (2%)
HER2 status
Not-amplified 198 (68%) 1031 (85%) 438 (89%) 50 (45%) 812 (69%)
Amplified 64 (22%) 162 (13%) 42 (9%) 10 (9%) 135 (12%)
Unknown 28 (10%) 21 (2%) 12 (2%) 52 (46%) 222 (19%)
Triple negative 50 (17%) 192 (16%) 39 (8%) 13 (12%) 64 (5%)
KI67
Not amplified 111 (38%) 0 175 (36%) 0 519 (44%)
Amplified 151 (52%) 0 286 (58%) 0 610 (52%)
Unknown 28 (10%) 1214 (100%) 31 (6%) 112 (100%) 40 (4%)
Abbreviations: PR-progesterone receptor, ER-estrogen receptor, HER2- receptor tyrosine-protein kinase 
erbB-2, IQR – Interquartile range
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Figure 2: FKBPL expression Kaplan-Meier estimates of breast cancer specific survival for FKBPL in (A) cohort I  
(n = 290) (B) cohort II (n = 1214) (C) cohort III (n = 492) (D) cohort IV (n = 104) and (E) cohort V (n = 1169). FKBPL 
histoscore was categorised into high and low groups using a cut-point of 190.
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patients (χ2 = 10.7, p = 0.03, Figure 4A). Using a one stage 
random effects model, patients with lower FKBPL levels 
have significantly shorter BCSS than those with high 
expression within the tamoxifen treated population (HR = 
1.25, 95% CI 1.04–1.49, p = 0.02, Figure 4A).
Evaluation of FKBPL expression and BCSS in 
ER positive patients
Similarly, there was some evidence of heterogeneity 
in the effect of FKBPL on BCSS across the five cohorts 
for the 2365 ER positive only patients (χ2 = 8.5, p = 0.07, 
Figure 4B). ER positive patients with low FKBPL 
expression had a significantly reduced BCSS compared 
with patients with high FKBPL levels (HR = 1.34, 95% CI 
1.13–1.58, p < 0.001, Figure 4B). FKBPL was a significant 
predictor of BCSS in the subgroup of 834 ER positive, 
node positive patients (HR = 1.41, 95% CI 1.12–1.77, 
p = 0.004). However, there was a borderline prognostic 
effect of FKBPL in the 1361 ER positive, node negative 
patients (HR = 1.27, 95% CI 0.98–1.65, p = 0.07) and a 
significant effect within the subgroup of 1148 ER positive, 
node negative, HER2 negative patients (HR = 1.35, 95% 
CI 1.01–1.79, p = 0.04).
Evaluation of FKBPL expression and RFI in 
tamoxifen treated and ER positive patients
Within the 1649 tamoxifen treated patients, 
FKBPL expression was only able to predict outcome in 
tamoxifen-treated patients for RFI within cohort III 
(p = 0.007) but not within cohorts I, II, IV and V (p = 0.09, 
0.60, 0.73 and 0.65 respectively, Figure 5A). Over all five 
cohorts, FKBPL expression was a borderline significant 
predictor of RFI in a random effects model (HR = 1.23, 
95% CI 0.99–1.54, p = 0.06, Figure 5A). However, 
FKBPL was significantly associated with RFI within the 
2365 ER positive patients (HR = 1.32, 95% CI 1.05–1.65, 
p = 0.02, Figure 5B).
The interaction of tamoxifen treatment and FKBPL 
was assessed within the 290 cohort I patients that were 
randomised between 2 years tamoxifen and observation, 
but the interaction term was not significant for predicting 
RFI (p = 0.46). In addition, there was no significant 
interaction between the use of tamoxifen treatment and 
FKBPL expression for RFI in all patients (p = 0.38).
Effects of TMA core loss on patient distribution
The characteristics of the patients with or without 
sample availability were similar and a sensitivity analysis 
using multiple imputations produced the same conclusions 
(data not shown).
DISCUSSION
The recent advances in gene expression profiling 
suggest an increasingly important role for its use in disease 
management [41, 42]. Despite these advances, there are 
a number of limitations, such as high cost, which mean 
Figure 3: Hazard ratio plot of breast cancer specific survival against FKBPL levels by cohort using a one stage random 
effects meta-analysis model (n = 3279).
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Figure 4: Hazard ratio plot of breast cancer specific survival against FKBPL levels by cohort using a one stage random 
effects meta-analysis model in (A) tamoxifen treated patients (n = 1649) and (B) ER-positive patients (n = 2365).
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Figure 5: Hazard ratio plot of relapse free interval against FKBPL levels by cohort using a one stage random effects 
meta-analysis model in (A) tamoxifen treated patients (n = 1649) and (B) ER-positive patients (n = 2365).
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that biomarker analysis using IHC remains the most 
commonly used method for tailoring cancer therapy [43]. 
Currently, there is a very limited panel of commonly 
used biomarkers; therefore it is essential to identify novel 
biomarkers, to further stratify patients with respect to 
prognosis or response to treatment.
This paper investigates the potential of FKBPL as 
a prognostic marker in breast cancer patients. We have 
previously presented data demonstrating an in vitro role 
for FKBPL in association with HSP90, where it has 
been associated with cell proliferation and sensitivity to 
endocrine therapies [23, 25, 26]. FKBPL mRNA levels 
were also previously shown to significantly prognosticate 
patient outcome, whilst there was a trend towards 
significance in relation to response to tamoxifen therapy 
[23]. Furthermore, loss of the region of chromosome 6, on 
which FKBPL is located, has been shown to occur more 
frequently in patients presenting with cancer recurrence 
within 5 years of diagnosis [44].
Our previous work has already demonstrated 
an association between FKBPL and survival in cohort 
III [32]; here, we evaluated four other cohorts (I, II, IV 
and V) using a systematic and standardised approach. 
FKBPL was clearly associated with BCSS in cohorts I 
(P = 0.004) and II (p = 0.04) and when cohort III (p = 
0.001) was reanalysed using a histoscore rather than 
staining intensity, an association was still observed. 
Histoscores were used so that statistical evaluation of 
FKBPL levels across all cohorts could be standardised 
and where percentage tumour stained could also be 
considered; thus allowing FKBPL to be categorised 
into low and high levels according to the median value 
of 190, across all cohorts. In cohorts IV and V, FKBPL 
did not significantly correlate with BCSS (p = 0.93 and 
p = 0.36 respectively). The variation between cohorts was 
probably due to small sample numbers available in cohort 
IV, and a poor distribution of intensity score in cohort 
V; both viable reasons for a lack of significance within 
these cohorts. Furthermore, we note that Cohort V had 
a higher proportion of patients with a positive PR status 
which may be affecting the high proportion of patients 
with high FKBPL levels. In addition, a larger proportion 
of patients were treated with tamoxifen (both ER positive 
and ER negatives) in Cohort V; it is difficult at this stage 
to determine whether these differences could impact on 
FKBPL’s prognostic ability within this cohort. However, 
with the significant increase in power achieved through the 
meta-analysis of all 3277 patients from the five cohorts, we 
were able to demonstrate that BCSS significantly differs 
across FKBPL levels, with low FKBPL expression having 
shorter BCSS (HR = 1.31, 95% CI 1.15–1.50, p < 0.001).
Interestingly, other members of the FK506-binding 
protein family (FKBPs) have also been implicated in 
cancer progression and have shown potential as cancer 
biomarkers. FKBP12 has been shown to stabilize the 
inactive form of tumor growth factor β (TGF-β) receptor 
1, inhibiting cell growth and differentiation, as well as 
apoptosis [45]. However unlike FKBPL, whose over 
expression has been shown to significantly improve 
overall survival, FKBP12 over expression is associated 
with a less favorable outcome. Whilst screening for 
angiogenesis-related proteins in malignant high-grade 
astrocytomas, FKBP12 was shown to be one of 17 genes 
upregulated [46].
FKBP51 is another FKBP which has been shown 
to play a role in steroid hormone signalling, where it 
displays both inhibitory [47] and stimulatory [48] roles. 
Furthermore, FKBP51 has also been associated with 
chemo- and radio-resistance in various cancers, including 
breast cancer. This is thought to be a result of FKBP51′s 
ability to dephosphorylate Akt, a protein kinase which 
promotes cell survival and inhibits apoptosis [49]. 
Additionally, other published in vitro analyses have 
demonstrated that decreased FKBP51 expression resulted 
in chemo-resistance in a variety of cancer cell lines, with 
these findings expected to translate into a clinical setting 
[50]. These findings are in line with our findings for 
FKBPL.
Based on previously published data [23], a role 
for FKBPL in prognosticating patient survival following 
endocrine therapy was anticipated. FKBPL has previously 
been shown to modulate cell sensitivity to tamoxifen 
treatment, with clonogenic survival of MCF-7 cells 
over expressing FKBPL being significantly less than the 
MCF-7 control. Following the meta-analysis, a significant 
association between high FKBPL expression and BCSS in 
patients treated with endocrine therapy was observed but 
not for RFI at this stage, as there were still too few events. 
The predictive potential of FKBPL was also examined 
within cohort I, where patients had either received 
tamoxifen treatment, or not. We were unable to see any 
significant correlation between FKBPL expression and 
response to tamoxifen therapy. It is therefore important to 
further explore the predictive ability of FKBPL within a 
larger patient population.
A major requirement of new biomarkers is their 
ability to function independently. Therefore multivariate 
analysis was carried out to determine whether the 
prognostic ability of FKBPL remained significant after 
adjusting for current markers. Our data demonstrates after 
adjusting for tumor size, grade, nodal status, ER and PR 
status and also HER2 status, FKBPL remains significant. 
Significance was also maintained after adjusting for NPI 
in four or the five cohorts, again suggesting that FKBPL 
adds additional prognostic information above current 
tools. Furthermore, the prognostic effect of FKBPL 
in the 1361 ER positive, node negative patients was 
borderline significant (p = 0.07) and significant within 
the subgroup of 1148 ER positive, node negative, HER2 
negative patients (p = 0.04). Currently, ER-positive, 
node-negative patients would be assigned to tamoxifen 
therapy. However, this data suggests that ER-positive, 
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node-negative patients, who also have low FKBPL 
expression, may have aggressive tumours and therefore 
benefit from adjuvant chemotherapy alongside tamoxifen 
treatment. It would also be interesting to further evaluate 
FKBPL’s association with outcome by determining the 
effects of differential FKBPL expression on response 
to different treatment regimes, for example endocrine 
therapy alone or in combination with chemotherapy. 
Unfortunately, the number of patients receiving a 
combination of chemo- and endocrine therapy within this 
analysis was too small (n = 164).
We have demonstrated a role for FKBPL in 
prognosticating BCSS within a large meta-analysis; 
however its ability to influence clinical management 
requires further investigation. Nevertheless, the data 
generated through this collectively large patient cohort 
support the emerging in vitro and in vivo data highlighting 
FKBPL’s anti-tumor activity [18, 19, 21, 24]. FKBPL has 
known anti-angiogenic [18, 19] and anti-cancer stem cell 
activity [21] and its over expression can slow the growth 
of breast tumors through stabilisation of p21 [25], so it’s 
prognostic ability is not surprising. In summary, we have 
demonstrated that our FKBPL IHC-biomarker is fit for 
purpose, portable and reproducible across laboratories, 
and could be scored using our automated algorithm that 
may allow for more precise cut-offs in decision making 
across these sites, in the future. Furthermore, these data 
provide support for the use of the FKBPL biomarker as 
a prognostic aid to patient management in early-stage 
ER+, LN-, Her2- breast cancer, which could be easily and 
cheaply incorporated alongside these standard biomarkers. 
Currently, this subgroup of patients would usually receive 
endocrine therapy alone. However, our data suggest 
that if FKBPL expression is low, their survival is worse 
than those with high FKBPL expression and therefore 
these patients may benefit from the addition of adjuvant 
chemotherapy.
MATERIALS AND METHODS
Patient characteristics
Individual patient data from five cohorts were 
obtained. These cohorts were selected as they were 
derived from breast cancer patients which had similar 
clinico-pathological features and patients had received 
similar treatment regimen. Data requested from all cohorts 
included survival and relapse information, endocrine 
treatment, and the characteristics of tumor size and grade, 
lymph node status, ER status, PR status, Her2 status and 
Ki67 where available.
Cohort I- Randomised control trial: The Swedish 
Randomised Study of 2 Years of Adjuvant Tamoxifen 
vs No Treatment recruited 564 patients between 1984 
and 1991. These were either premenopausal or under 
50 years with stage 2 invasive breast cancer, treated by 
radical mastectomy or breast-conserving surgery including 
axillary node clearance [27]. Those suitable for breast-
conservation were treated with radiotherapy (50Gy), whilst 
patients with axillary node metastases received additional 
regional radiotherapy. Patients were randomly assigned 
between groups, with 288 patients in the control arm who 
received no treatment and 276 patients receiving 2 years 
of adjuvant tamoxifen, 20–40 mg daily. Less than 2% 
(n = 9) of patients received adjuvant poly-chemotherapy. 
The aim of this clinical trial was to examine the effect 
of tamoxifen on recurrence free survival (RFS) and the 
study has been described in detail elsewhere, including 
as part of the Oxford meta-analysis [28, 29]. The study 
was approved by the ethical committees at Lund and 
Linköping Universities. Of the 440 patients represented on 
the TMAs, only 290 patients were available for analysis 
due to core loss during sectioning and staining.
Cohort II- Nottingham cohort: This is a well-
characterised consecutive series of patients treated 
according to standard clinical protocols and has been 
reported upon previously [30]. The cohort consisted of 
1902 early stage invasive breast cancer patients treated 
at Nottingham University Hospitals, between 1987 and 
1998. The median age of patients was 55 years (range 
18–72) with a high proportion having stage 1 disease 
(1203/1902). All patients underwent a mastectomy 
or wide local excision, followed by radiotherapy if 
indicated. Patients received systemic adjuvant treatment 
on the basis of the NPI, ER and menopausal status. 
Patients with an NPI value of less than 3.4 did not receive 
adjuvant therapy and patients with an NPI value of 3.4 
were candidates for cyclophosphamide, methotrexate and 
5-fluorouracil chemotherapy if they were ER negative or 
premenopausal and for endocrine therapy if they were ER 
positive. Endocrine therapy included either tamoxifen, or 
a combination of tamoxifen and goserelin acetate. Of the 
1902 patients, 1214 patients were available for analysis 
due to core loss during sectioning and staining or there 
being insufficient tumor to score accurately.
In addition, a training TMA (n = 200) from 
Nottingham was also used to assess suitability of TMAs 
against matched full face breast cancer sections on two 
separate runs and to assess inter-lab variability of staining 
and scoring.
Cohort III- Swedish Malmö Cohort: The Swedish 
Malmö cohort consisted of 512 consecutive breast cancer 
cases diagnosed at the Department of Pathology, Malmö 
University Hospital, Malmö, Sweden, between 1988 and 
1992 and has been described previously [31]. The median 
age was 65 years (range 27 – 96). Complete treatment data 
were available for 379 (76%) patients, 160 of whom had 
received adjuvant tamoxifen. Twenty three patients received 
adjuvant chemotherapy. Two hundred patients received no 
adjuvant systemic treatment. All invasive TNM stages were 
represented within the cohort. Five hundred of 512 patients 
were represented on TMAs, with 492 cores being scoreable. 
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Survival analysis for this cohort has been previously 
published and reported using FKBPL staining intensity rather 
than histoscore [32]; alternative cut-offs were used here.
Cohort IV- Waterford retrospective cohort: Tissue 
was obtained as part of a retrospective study from the 
Waterford Regional Hospital between 1998 and 2004. 
The median age was 56 years (range 26 to 84). The cohort 
consisted of 292 patients treated with radical mastectomy 
or breast-conserving surgery including axillary node 
sampling and clearance. Those suitable for breast-
conservation were treated with radiotherapy. Excluded 
from the analysis were patients who did not have breast 
surgery, those who had neoadjuvant therapy, or those 
whose tissue specimens were irretrievable. Follow-up 
data, average 8.4 years, was collected on the patients 
to determine disease free survival (DFS) and overall 
survival. One hundred and twelve patients were available 
for analysis where FKBPL was measured and 87 of them 
were ER positive and received endocrine treatment.
Cohort V- Breast Conservation Surgery (BCS) 
cohort: Tissue obtained from the Edinburgh BCS 
comprised of a consecutive cohort of 1812 patients treated 
by breast conservation surgery, axillary node sampling or 
clearance, and whole breast radiotherapy between 1981 
and 1998. Patients were those considered suitable for 
breast-conserving therapy and were T1 or T2 (<30 mm), 
N0 or N1 and M0 for conventional tumour node metastasis 
staging. Post-operative breast radiotherapy was given 
over 4–5 weeks at a dose of 45 Gy in 20–25 fractions. 
Patients received adjuvant systemic therapy as follows: 
tamoxifen, other endocrine therapy, chemotherapy alone, 
chemotherapy plus endocrine therapy, no adjuvant systemic 
therapy. A total of 1169 patients were available for analysis 
due to variable core loss between centers, which resulted 
from extensive use of TMAs in previous studies.
Tissue microarray construction
All TMAs were constructed at each of the 
various centres; cohort I-Lund University [33], cohort 
II- Nottingham University [30], cohort III- Malmö 
University Hospital [31], cohort IV- Waterford Regional 
Hospital and cohort V- Edinburgh Breast Unit [34]. In 
brief, TMAs were constructed using standard formalin-
fixed, paraffin-embedded tissue sections of primary breast 
carcinoma. Single (cohort II and cohort III), duplicate 
(cohort I), triplicate (cohort V) and quadruplicate (cohort 
IV) cylindrical cores with a diameter of 0.6 mm were 
taken from areas showing tumor on slides stained for 
haematoxylin and eosin. The number of cores on the 
recipient blocks varied between cohorts.
Immunohistochemistry staining of tissue
Tissue staining was carried out in various locations, 
as follows. For optimisation of staining and scoring, this 
was carried out at the three main centres, Belfast, Toronto 
and Dublin as described below. Cohort I was stained at 
the Northern Ireland Molecular Pathology Laboratory of 
Queen’s University Belfast, Centre for Cancer Research 
and Cell Biology, using the Ventana Discovery XT 
Immunostainer (VentanaMedical Systems Inc, Arizona, 
USA). Standard IHC techniques were used to stain 
the TMA with the FKBPL antibody (1:800), with an 
incubation period of 1 h. Cohort II was stained manually, 
following antibody optimisations, at the University 
of Nottingham. Following initial processing, FKBPL 
antibody was added at a dilution of 1:100 for one hour 
and the Novolink Polymer Detection Kit (Leica) used. 
Positive and negative controls were included. Cohort 
III was stained as previously described [20]. Cohort IV 
was stained manually, as previously described [35], at 
the Royal College of Surgeons Ireland, Dublin, using an 
antibody dilution of 1:100 and incubation period of 1 h. 
Finally, cohort V was stained at the Ontario Institute of 
Cancer Research, Toronto, with the FKBPL antibody 
(1:600) using the Benchmark XT staining system (Ventana 
Medical Systems Inc, Arizona, USA), with an incubation 
period of 1 h.
For all cohorts, staining was visualised with 3, 
3-diaminobenzidine (DAB) and lightly counterstained 
using hematoxylin. Following staining, TMAs were 
securely stored shielded from light at room temperature.
Evaluation of immunohistochemical staining
In order to confirm that the staining and scoring 
methodology for FKBPL analysis was robust, training 
TMAs were constructed using a sample of tumor cores 
(n = 200) provided by Nottingham University. IHC staining 
of these TMAs was carried out at three different locations, 
Belfast, Dublin and Toronto on three independent 
platforms, on consecutively cut sections and scored 
blinded by four independent scorers. Similarly, FKBPL 
staining was evaluated on matched full face sections. In 
order to determine the reliability of manual IHC evaluation 
of FKBPL staining, we utilized image analysis software to 
quantitatively score FKBPL cytoplasmic staining within 
263 tumour cores from cohort I.
TMAs were scored fully by one ‘trained’ scorer, with 
a second, independent scorer evaluating a minimum of 10% 
of the cohort. Each scorer was ‘blind’ to all pathological 
information, as well as the others scores. FKBPL staining 
was localised to the cytoplasm of tumor cells and scored 
according to staining intensity. Cores were assigned overall 
FKBPL staining intensity scores; 0, 1+, 2+ or 3+ providing 
over 20% of the core consisted of tumor tissue (Figure 1B). 
In addition, cores were also awarded the percentage of 
tumor stained with FKBPL and from this a histoscore 
was calculated, where intensity scores were multiplied 
by percentage of core stained, with a maximum value of 
300. For generation of automated scores, high resolution 
digital images were captured using the ScanScope XT 
slide scanner (Aperio Technologies, now part of Leica 
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Biosystems). TMA images were dearrayed and managed 
using Spectrum software (Aperio Technologies) and a color 
deconvolution algorithm (Aperio Technologies) was used to 
develop a quantitative scoring model of FKBPL expression. 
Scoring results were established prior to transfer to the 
independent statistics team at the University of Warwick 
for analysis with the clinical outcome data.
Statistics
The FKBPL histoscores were categorised into 
low and high levels according to the median value of 
190, across all cohorts. Agreement between scorers was 
assessed by ICCC, obtained from a two-way random 
effects model for the absolute agreement using SPSS 
statistical software package (IBM SPSS Statistics 19). 
ICCC values can range between 0–1.0, with values of 0.6 
being acceptable and above 0.70 taken to confirm good 
agreement between scorers [36]. Similarly, ICCCs were 
calculated to assess agreement between the results of full 
face sections and manual scores on two separate occasions 
and a box and whisker plot constructed.
In order to compare manual FKBPL cytoplasmic 
scoring with automated image analysis, a box and whisker 
plot for the automatic scoring values was plotted against 
the manual score separately for each manual scorer. A 
random effects model accounting for the manual scoring 
groups was fitted to obtain an ICCC as a measure of 
the homogeneity of the automatic scores within manual 
scoring groups.
BCSS was calculated as the time from diagnosis 
until the date of death from breast cancer or censored at 
the date of death if died of other causes or the date last 
known to be alive. RFI was calculated as the time from 
diagnosis until the date of first relapse or date of breast 
cancer death if died without recorded relapse. Survival 
analyses were performed using the SAS statistical package 
(version 9.3). For each cohort, Kaplan-Meier survival 
curves were constructed for BCSS and RFI and compared 
across FKBPL expression groups using a log rank test.
To assess the prognostic ability of FKBPL across 
cohorts a hazard ratio plot was constructed and the 
Cochran’s Q statistic was used to assess the level of 
heterogeneity between cohorts and the need for a random 
effects model [37]. A one stage random effects Cox 
regression model [38] was undertaken using the R statistical 
software (version 3.0.3) when there was some evidence of 
heterogeneity to assess the prognostic ability of FKBPL. 
The effect of FKBPL after adjusting for known prognostic 
factors including; tumor size, grade, nodal status, ER and 
PR status was also determined. Time dependent covariates 
were fitted when the proportional hazards assumption 
failed. Analyses were also performed within the tamoxifen 
treated patients and ER positive patients. The interaction 
of tamoxifen treatment and FKBPL on RFI was considered 
for all five cohorts and more specifically within the 290 
cohort I only patients that were randomised to have two 
years tamoxifen versus observation.
Due to samples only being available on a proportion 
of patients within each cohort, a sensitivity analysis was 
performed to assess the stability of the results using 
multiple imputation using a fully conditional specification 
method [39] within SAS (version 9.3) statistical package 
with 20 imputations and the results combined using 
Rubin’s rules [40].
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